Category

Cytomegalovirus (“CMV”)

VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards

By | Cytomegalovirus ("CMV"), Glioblastoma ("GBM"), Press Releases, Sci-B-Vac®
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SABs) consisting of leading experts in infectious disease and immuno-oncology research and vaccine...
Read More